With Mod­er­na wind­fall, Har­vard pro­fes­sor and in­te­grins leg­end Tim Springer do­nates $210M to his In­sti­tute for Pro­tein In­no­va­tion

Tim Springer, with his name sta­pled to the likes of Mod­er­na, Schol­ar Rock and Ed­i­tas Med­i­cine, plus the foun­da­tion­al work for Take­da’s ul­cer­a­tive col­i­tis and Crohn’s dis­ease med En­tyvio, has had a lot on his plate over the past five decades.

In 2020, the Har­vard pro­fes­sor be­came a bil­lion­aire thanks to ear­ly in­vest­ing in Mod­er­na and hav­ing prof­it­ed a cou­ple hun­dred mil­lion ear­li­er in his ca­reer off his com­pa­ny LeukoSite’s sale to Mil­len­ni­um Phar­ma­ceu­ti­cals be­fore the turn of the cen­tu­ry.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER